SLC28A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Inosine (SCHEMBL222073)	0.67	2/20
Adenosine (SCHEMBL192733)	0.63	2/20
Acetone (SCHEMBL472736)	0.62	2/20
SCHEMBL66047	0.56	2/20
SCHEMBL439243	0.56	2/20
Adenosine (SCHEMBL438282)	0.55	2/20
SCHEMBL481525	0.55	2/20
SCHEMBL454216	0.54	2/20
SCHEMBL41360	0.53	2/20
SCHEMBL397799	0.53	2/20
Acetone (SCHEMBL472703)	0.52	2/20
SCHEMBL226040	0.52	2/20
SCHEMBL120550	0.51	2/20
SCHEMBL42103	0.50	2/20
SCHEMBL120561	0.50	2/20
SCHEMBL160357	0.50	2/20
SCHEMBL160359	0.50	2/20
SCHEMBL288517	0.50	2/20
SCHEMBL199259	0.49	2/20
Phosphoric Acid (SCHEMBL216583)	0.48	2/20

Clinical trials — most relevant to SLC28A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ticagrelor in Remote Ischemic Preconditioning Study	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure	PHASE4	RECRUITING
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes	PHASE2	COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin	PHASE2	NOT_YET_RECRUITING
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia	PHASE2	COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Renal Transporters After Renal Transplantation	nan	UNKNOWN
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	nan	UNKNOWN
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients	nan	COMPLETED
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity	nan	RECRUITING
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.	nan	RECRUITING
Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction	nan	COMPLETED
SLC6A1-NDD Prospective Longitudinal Natural History Study	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC28A1 binder may also engage these)

Protein	Name	Similarity
E9PXX9	—	1.000	E9PXX9 →
Q62674	—	1.000	Q62674 →
Q62773	—	1.000	Q62773 →
O62667	—	1.000	O62667 →
SLC28A2	Sodium/nucleoside cotransporter 2	0.998	landscape →
O88627	—	0.996	O88627 →
Q9MZT2	—	0.996	Q9MZT2 →
Q8VIH3	—	0.992	Q8VIH3 →
SLC28A3	Solute carrier family 28 member 3	0.990	landscape →
Q9ERH8	—	0.988	Q9ERH8 →
Q9UA35	—	0.988	Q9UA35 →
P23977	—	0.986	P23977 →
Q61327	—	0.985	Q61327 →
O18875	—	0.985	O18875 →
Q96N87	—	0.985	Q96N87 →
P48029	—	0.985	P48029 →
O88575	—	0.985	O88575 →
P31661	—	0.985	P31661 →
B0JZG0	—	0.984	B0JZG0 →
P23562	—	0.983	P23562 →
Q9GJT6	—	0.983	Q9GJT6 →
SLC6A4	Sodium-dependent serotonin transporter	0.983	landscape →
P28570	—	0.983	P28570 →
SLC6A3	Sodium-dependent dopamine transporter	0.982	landscape →
Q6IFT6	—	0.982	Q6IFT6 →
Q8VBW1	—	0.982	Q8VBW1 →
Q9MYX0	—	0.982	Q9MYX0 →
P31649	—	0.982	P31649 →
Q91502	—	0.982	Q91502 →
SLC9A3	Sodium/hydrogen exchanger 3	0.982	landscape →